Survival of patients with cutaneous T-cell lymphoma after treatment with extracorporeal photochemotherapy.

Wollina, Uwe; Liebold, K.; Kaatz, Martin; Looks, A.; Stuhlert, A.; Lange, D.

doi:10.3892/or.7.6.1197

Cited by 11 publications

(16 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A retrospective analysis of our own data suggested that responders to ECP show a prolonged OS of 29 months 77 . This supports the proposal that ECP may affect a vaccination‐like restoration of immune surveillance.…”

Section: Treatment Of Ctclsupporting

confidence: 84%

Cutaneous T cell lymphoma: update on treatment

Wollina

2012

Int J Dermatology

View full text Add to dashboard Cite

show abstract

Section: Treatment Of Ctclsupporting

confidence: 84%

Cutaneous T cell lymphoma: update on treatment

Wollina

2012

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…Previous analysis of the North American ECP experience found no significant response of clinical stage IIB CTCL (tumor stage with no lymph node involvement) or tumor skin stage T3 to ECP (11). The present combined analysis includes the European experience where the response rates for tumor stage disease are more favorable, ranging from 0% to 100% in five series (36,38–41). Therefore, the combined response rate in Table 2 for stage IIB patients is not a true reflection of the dichotomous observations across the continents: overall response, 52.6%; and complete response, 26.3%.…”

Section: Photopheresis Efficacy In Mycosis Fungoides and Sézary Syndromementioning

confidence: 99%

“…There is controversy surrounding the use of ECP in early stage patients with CTCL, particularly those without circulating Sézary cells (11,14,42). Out of 25 patients in Table 2 with generalized patch/plaque stage IB CTCL, 64.0% responded, 28% achieved a complete response, and only one or two patients had blood smears showing greater than 5% Sézary cells (13–15,28,38–40,43). Although this may imply that blood involvement is not necessary to respond to ECP, whether or not these IB patients showed evidence of T‐cell clones by gene rearrangement studies of peripheral blood is unknown.…”

Section: Photopheresis Efficacy In Mycosis Fungoides and Sézary Syndromementioning

confidence: 99%

The treatment of cutaneous T-cell lymphoma with photopheresis

Zic¹

2003

Dermatol Ther

123

107

View full text Add to dashboard Cite

Photopheresis or extracorporeal photochemotherapy (ECP) is an immunomodulating procedure that has been available for the treatment of cutaneous T-cell lymphoma (CTCL) since 1987. A concentrated white blood cell (WBC) sample spiked with 8-methoxypsoralen (methoxsalen) is exposed to an ultraviolet A light source, then all blood components are returned to the patient. Treatment of mycosis fungoides (MF) and Sézary syndrome (SS) with ECP has been reported in over 400 patients. The combined overall response rate for all stages of CTCL is 55.7% (244 out of 438) with 17.6% (77 out of 438) achieving a complete response. Efficacy in treating certain clinical stages (IB, IIA, III and IVA) and skin stages (T2 and T4) of MF and SS is favorable, although randomized trials comparing ECP to other standard therapies are needed. The use of ECP to treat early stage patients remains controversial. Efforts to establish the effectiveness of combining ECP with other newer immunoadjuvant therapies and modifications of the procedure to enhance immunomodulation are exciting prospects for patients with CTCL.

show abstract

“…Monotherapy with interferon-alfa also shows a significant response rate (21 of 51 complete responses) in patients treated at a variety of disease stages. Finally, extracorporeal photochemotherapy may also offer a therapeutic option for patients with both early and advanced stage disease [50]. Recently, DAB 389 IL-2, a fusion protein containing both interleukin (IL)-2 and diphtheria toxin, has been developed and approved for use in mycosis fungoides [51•,52•,53].…”

Section: Treatmentmentioning

confidence: 99%

T-small cell disorders

Westin

Longo

2001

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

A minority (less than 2%) of all lymphoproliferative disorders are derived from small T cells. These include T-cell prolymphocytic leukemia, T-cell granular lymphocytic leukemia, and mycosis fungoides/Sézary syndrome. With the possible exception of early-stage, skin-localized mycosis fungoides, all are considered incurable, although palliation can be achieved with radiation therapy, chemotherapy, biologic therapy, and combinations of these modalities. Of these disorders, mycosis fungoides is the most common; it follows an indolent, though gradually progressive, course that spans years. The T-cell prolymphocytic leukemias, in contrast, are generally refractory to treatment, with a median survival of typically less than 1 year. Although effective therapy remains elusive in most cases, the development of nucleosides as a class of chemotherapeutic agents and biologics, including interferon, monoclonal antibodies, and vitamin A derivatives, offers new hope for at least more effective palliation of these progressive lymphoproliferative disorders. However, rapid improvement in the treatment of these disorders remains hampered by the rarity of these individual entities. More rapid progress in treatment depends on national and international cooperation to accrue patients for definitive trials of sufficient size to evaluate new treatment options quickly.

show abstract

Survival of patients with cutaneous T-cell lymphoma after treatment with extracorporeal photochemotherapy.

Cited by 11 publications

References 5 publications

Cutaneous T cell lymphoma: update on treatment

Cutaneous T cell lymphoma: update on treatment

The treatment of cutaneous T-cell lymphoma with photopheresis

T-small cell disorders

Contact Info

Product

Resources

About